Statute Details
- Title: Health Products (Clinical Trials) Regulations 2016
- Act Code: HPA2007-S331-2016
- Legislation Type: Subsidiary legislation (SL)
- Enacting Authority: Health Sciences Authority (with Minister for Health approval)
- Enabling Act: Health Products Act (section 72)
- Commencement: 1 November 2016
- Status: Current version as at 27 March 2026
- Parts: Part 1 (General); Part 2 (Clinical trials of therapeutic products or applicable CTGT products); Part 3 (Miscellaneous); Part 4 (Offences); Part 5 (Application to pending clinical trials)
- Key Definitions (examples): “adverse event”, “adverse drug reaction”, “CTGT product”, “applicable CTGT product”, “investigational product”, “auxiliary product”, “clinical trial in an emergency situation”
- Key Provisions (high level): authorisation/notification regime; sponsor and principal investigator duties; consent requirements; good clinical practice; safety/vigilance reporting; record-keeping; labelling; confidentiality and publication; offences
What Is This Legislation About?
The Health Products (Clinical Trials) Regulations 2016 (“CTR Regulations”) set out Singapore’s regulatory framework for conducting clinical trials involving health products—particularly therapeutic products and certain cell, tissue and gene therapy (CTGT) products. In practical terms, the Regulations control how trials are planned, authorised (or notified), run, monitored, and reported to the Health Sciences Authority (“HSA”).
The Regulations aim to protect trial subjects and ensure that clinical trials are conducted to acceptable scientific and ethical standards. They do this by requiring sponsors and investigators to follow good clinical practice, obtain appropriate informed consent (including special rules for emergencies), implement urgent safety measures when risks emerge, and report safety information such as serious adverse events and unexpected serious adverse drug reactions.
While the Regulations are technical, their core message is straightforward: if you want to test an investigational product on human subjects in Singapore, you must comply with a structured approval/notification process and maintain robust safeguards throughout the trial lifecycle—from protocol and labelling to vigilance reporting and records.
What Are the Key Provisions?
1) Scope and who must comply. The Regulations apply to clinical trials of specified products that are not observational. The scope provision (regulation 3) is critical because it determines whether a study is regulated as a “clinical trial” under this framework. For practitioners, the first step is classification: is the product a therapeutic product or an applicable CTGT product, and is the study interventional (as opposed to observational)? If yes, the CTR Regulations become the governing compliance baseline.
2) Authorisation or notification for starting a trial. A central feature is the regulatory submission pathway. Regulation 7 establishes the requirement for authorisation for, or notification of, a clinical trial. The distinction matters: authorisation implies HSA approval before the trial can proceed, while notification implies a different regulatory posture (typically still requiring compliance with conditions and duties, but without the same pre-approval step). Regulations 8 and 9 then govern the mechanics—how to apply for authorisation and how to notify HSA.
3) Amendments, substantial amendments, and safety-driven changes. Trials evolve. Regulation 10 addresses amendments and substantial amendments to clinical trials, requiring sponsors to manage changes to protocol and trial documentation in a controlled manner. This is essential for legal defensibility: if a protocol change affects subject risk, endpoints, dosing, or eligibility criteria, it may trigger additional regulatory steps. Regulation 11 further requires notification of serious breaches and urgent safety measures, ensuring that HSA is promptly informed when trial conduct departs from requirements or when immediate actions are needed to protect subjects.
4) Sponsor and investigator responsibilities; good clinical practice. The Regulations impose structured duties on sponsors and investigators. Regulations 4 and 5 identify the sponsor and the principal investigator (and related roles). Regulation 6 requires an investigator’s brochure, which is a core document summarising relevant preclinical and clinical information about the investigational product. This brochure supports informed consent and safe trial conduct.
Regulation 13 requires that clinical trials be conducted in accordance with good clinical practice. Regulation 14 then ties conduct to the authorisations and notifications granted to the trial—meaning the protocol and conditions approved/accepted by HSA become binding operational requirements. Regulation 15 addresses the place of clinical trial, which is important for ensuring that trial sites meet the necessary standards and are properly designated.
5) Consent and information duties (including emergencies). Ethical compliance is a major pillar. Regulation 16 requires consent of subjects in clinical trials. Regulation 18 sets general requirements as to consent, while regulation 19 imposes a duty to give full explanation and information. These provisions are designed to ensure that subjects understand the nature of the trial, risks, and their rights.
Regulation 17 addresses consent in emergency situations. It defines a “clinical trial in an emergency situation” (in the definitions section) as one where subjects face life-threatening conditions, cannot consent due to medical condition, and it is not feasible to obtain consents from legal representatives within the window period. For practitioners, this is a high-risk compliance area: the Regulations require careful justification that the emergency criteria are met and that consent processes are handled in a legally compliant manner.
Regulation 20 prohibits coercion. This is significant because it provides a compliance hook for enforcement where consent is obtained through improper pressure or inducement.
6) Safety monitoring, urgent safety measures, and trial suspension/termination. Regulations 21 and 22 focus on subject protection. Regulation 21 requires urgent safety measures—actions to protect subjects when new risks arise. Regulation 22 provides for suspension or termination of a clinical trial, which may be required where continuing the trial would expose subjects to unacceptable risk or where regulatory conditions are not met.
7) Records, traceability, and vigilance reporting. Regulation 23 requires a record of clinical trials. This is essential for audits, inspections, and legal accountability. Regulation 23A adds traceability of applicable CTGT products used in clinical trials, reflecting the heightened complexity and supply-chain sensitivity of cell, tissue and gene therapy products.
Vigilance duties are set out in Division 4. Regulation 24 requires notifications of serious adverse events, and regulation 25 requires notifications of unexpected serious adverse drug reactions. These reporting obligations ensure that HSA receives timely safety information to assess whether trial conduct or product risk profiles require regulatory action.
8) Labelling requirements. Regulation 26 governs labelling of the investigational product and any auxiliary product. Labelling is not merely operational; it is a safety and traceability control. Incorrect labelling can lead to dosing errors, mix-ups, and compromised subject safety. The Second Schedule further sets out labelling requirements, which practitioners should treat as a compliance checklist.
9) Confidentiality and publication. Regulation 27 protects confidential information, balancing transparency with commercial and personal privacy concerns. Regulation 28 addresses publication of information on clinical trials, supporting public access to trial information while maintaining appropriate confidentiality safeguards.
10) Offences. Part 4 (regulation 29) creates offences for non-compliance. While the extract does not list offence elements, the existence of an offences section signals that breaches of authorisation/notification duties, consent requirements, safety reporting, record-keeping, labelling, or confidentiality obligations can attract criminal or regulatory penalties. For counsel, this elevates the importance of documented compliance systems and timely reporting.
11) Pending clinical trials. Part 5 (regulation 30) addresses how the Regulations apply to pending clinical trials. This transitional provision is crucial when advising sponsors mid-study at the time of amendments or when determining which version of the rules applies to ongoing trials.
How Is This Legislation Structured?
The CTR Regulations are organised into five parts:
Part 1 (General) contains the citation and commencement, definitions, and the scope of the Regulations.
Part 2 is the operational core. It is divided into:
- Division 1 (General): sponsor and principal investigator roles; investigator’s brochure.
- Division 2 (Regulatory submissions): authorisation/notification; applications; notifications; amendments; serious breaches and urgent safety measures; status updates.
- Division 3 (General duties): good clinical practice; conduct in accordance with authorisations/notifications; trial site requirements; consent and information duties; safety duties including urgent safety measures and suspension/termination; record-keeping and traceability.
- Division 4 (Vigilance): serious adverse event and unexpected serious adverse drug reaction reporting.
- Division 5 (Labelling): labelling of investigational and auxiliary products.
Part 3 (Miscellaneous) covers confidentiality and publication.
Part 4 (Offences) sets out offences for contraventions.
Part 5 (Application to pending clinical trials) provides transitional application rules.
Two schedules support the Regulations: the First Schedule sets out principles of good clinical practice, and the Second Schedule sets out labelling requirements.
Who Does This Legislation Apply To?
The Regulations apply to parties involved in regulated clinical trials in Singapore—most notably sponsors and investigators (including the principal investigator and other trial personnel as relevant). The obligations are not limited to trial sites; sponsors must manage regulatory submissions, amendments, and safety reporting, while investigators must ensure trial conduct aligns with protocol, consent requirements, and good clinical practice.
In addition, the Regulations apply to trials involving therapeutic products and applicable CTGT products (as defined by reference to the CTGT product classification regime). The scope excludes observational clinical trials, meaning that interventional studies are the primary target of the regulatory framework.
Why Is This Legislation Important?
For practitioners, the CTR Regulations are important because they translate ethical and scientific expectations into enforceable legal duties. They provide the legal architecture for subject protection: informed consent, prohibition of coercion, urgent safety measures, and the ability (and duty) to suspend or terminate trials when risks arise.
From a compliance and litigation risk perspective, the Regulations also create clear documentation and reporting obligations. Record-keeping (regulation 23), traceability for CTGT products (regulation 23A), and vigilance reporting (regulations 24 and 25) are the backbone of post-incident accountability. If adverse outcomes occur, the sponsor’s ability to demonstrate timely reporting and adherence to protocol and labelling requirements will be central to regulatory and legal assessments.
Finally, the authorisation/notification regime and the offences provision mean that non-compliance is not merely a “best practice” issue. Counsel advising sponsors, CROs, and investigators should treat the CTR Regulations as a compliance system requiring governance: version control for protocols and amendments, consent training and templates, labelling verification procedures, and a vigilance workflow capable of meeting notification timelines.
Related Legislation
- Health Products Act (CHAPTER 122D)
- Healthcare Services Act 2020
- Human Biomedical Research Act 2015
- Medical Registration Act 1997
- Dental Registration Act 1999
- Health Products (Cell, Tissue and Gene Therapy Products) Regulations 2021 (referenced for CTGT classification)
Source Documents
This article provides an overview of the Health Products (Clinical Trials) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.